Zymeworks Inc (NASDAQ:ZYME) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued on Thursday.

According to Zacks, “Zymeworks Inc. is a clinical-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The companys lead product candidate includes ZW25 and ZW33 which are in clinical trial stage. Zymeworks Inc. is headquartered in Vancouver, Canada. “

A number of other research analysts have also recently weighed in on the stock. Cormark reaffirmed a “buy” rating on shares of Zymeworks in a research report on Saturday, September 30th. Scotiabank cut shares of Zymeworks from an “overweight” rating to an “underweight” rating in a research report on Thursday, September 7th. Finally, Barclays PLC reaffirmed an “underweight” rating and set a $8.00 price target on shares of Zymeworks in a research report on Thursday, September 7th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company’s stock. Zymeworks has a consensus rating of “Hold” and a consensus price target of $16.00.

Shares of Zymeworks (NASDAQ:ZYME) opened at 8.9022 on Thursday. Zymeworks has a 52 week low of $6.25 and a 52 week high of $14.25. The stock’s market cap is $225.57 million. The company’s 50-day moving average is $8.27 and its 200 day moving average is $9.05.

WARNING: “Zacks Investment Research Upgrades Zymeworks Inc (ZYME) to Hold” was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another publication, it was stolen and republished in violation of United States & international trademark and copyright laws. The correct version of this piece can be read at https://www.thecerbatgem.com/2017/10/14/zacks-investment-research-upgrades-zymeworks-inc-zyme-to-hold.html.

A number of hedge funds have recently made changes to their positions in ZYME. OxFORD Asset Management LLP acquired a new position in shares of Zymeworks during the second quarter worth $154,000. Sentry Investments Corp. acquired a new position in shares of Zymeworks during the second quarter worth $206,000. Barometer Capital Management Inc. acquired a new position in shares of Zymeworks during the second quarter worth $484,000. Finally, Franklin Resources Inc. acquired a new position in shares of Zymeworks during the second quarter worth $6,878,000.

Zymeworks Company Profile

Zymeworks Inc is a Canada-based clinical-stage biopharmaceutical company. The Company focuses on the discovery, development and commercialization of multifunctional biotherapeutics. The Company’s ZymeCAD platform is for protein modeling and structure-guided protein engineering. The Company’s platforms include Azymetric Platform, AlbuCORE Platform, EFECT Platform and Zymelink Conjugation Platform + Cytotoxins.

Analyst Recommendations for Zymeworks (NASDAQ:ZYME)

Receive News & Stock Ratings for Zymeworks Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zymeworks Inc and related stocks with our FREE daily email newsletter.